Report
Merus FIRST LOOK: 1Q25 results as expected, looking out toward ASCO update
Merus announced its 1Q25 results, highlighting ongoing clinical trials and financial performance. The Ph2 trial of Peto in combination with Keytruda for head and neck cancer is progressing, with an update expected at ASCO 2025. The two Ph3 trials for head and neck cancer continue enrolling, with substantial enrolment expected by year-end 2025. With $ 638m in cash, Merus reiterates its cash runway into 2028. We reiterate our $ 59 TP/Buy.
Underlying
MERUS B V
Provider
KBC Securities
We are a financial services provider for several types of professional clients, each with distinct needs.
Thomas Vranken
Other Reports on these Companies
Other Reports from KBC Securities
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.